PSA screening - Current controversy

Annals of Oncology

Volumn 9, Issue 12, 1998, Pages 1283-1288

  Svetec, D ^a   Thompson, I M ^b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Outcomes; Prostate cancer; Screening

Indexed keywords

CANCER SCREENING; HEALTH CARE COST; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME;

BRACHYTHERAPY; CARCINOMA; COST-BENEFIT ANALYSIS; DIAGNOSTIC TESTS, ROUTINE; DISEASE PROGRESSION; HUMANS; MALE; MASS SCREENING; MORTALITY; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOISOTOPE TELETHERAPY; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 0032412484     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008446208963     Document Type: Review

References (4)

1. Catalona WJ, Smith DS, Ratliff TL et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen based screening. JAMA 1993; 270: 948.
2. Smart CR. The results of prostate carcinoma screening in the US as reflected in the Surveillance, Epidemiology, and End Results Program. Cancer 1997; 80: 1835.
3. Landis SH, Murray T, Bolder S et al. Cancer Stat 1998. CA 1998; 48: 6.
4. Roberts RO, Jacobsen SJ, Katusic SK et al. Recent declines in prostate cancer incidence and mortality in Olmstead County, MN, 1980-1995. J Urol 1998; 159: 474A.